Literature DB >> 16242592

Incidence of TB in inmates with latent TB infection: 5-year follow-up.

Mary C White1, Jacqueline P Tulsky, Enrique Menendez, Joe Goldenson, L Masae Kawamura.   

Abstract

BACKGROUND: Inmates are a high-risk population for tuberculosis (TB) control efforts, including treatment for latent tuberculosis infection (LTBI). Completion of therapy after release has been poor. The goal of this study was to evaluate therapy completion and active disease over 5 years in a cohort of inmates.
METHODS: The sample was from a completed randomized trial in 1998-1999 of education or incentive versus usual care to improve therapy completion after release from the San Francisco County Jail. Records from the jail, the County Tuberculosis Clinic, and the California TB Registry were used to measure therapy completion and development of active TB. Analyses were conducted in 2005.
RESULTS: Of a total 527 inmates, 31.6% (n=176) completed therapy, of whom 59.7% (n=105) completed it in jail. Compared with the U.S.-born, foreign-born inmates residing in the United States for < or =5 years were less likely to complete the therapy (adjusted odds ratio [AOR]=0.49, 95% confidence interval [CI]=0.28-0.85), and those with more education were more likely to complete the therapy (AOR=1.06, 95% CI=1.01-1.12). Three subjects developed active TB in the 5 years of follow-up, resulting in an annual rate of 108 per 100,000. Compared with California rates, subjects were 59 times as likely to develop active TB (standardized morbidity ratio of 59.2, 95% CI=11.2-145.1). None had completed therapy, none were new immigrants, and two were known to be HIV-positive at diagnosis.
CONCLUSIONS: Completion of therapy for LTBI is a challenge, but the active TB seen in this jail cohort emphasizes the importance of continued efforts to address TB risk in this population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242592     DOI: 10.1016/j.amepre.2005.06.014

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  6 in total

1.  Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience.

Authors:  Y Hirsch-Moverman; J Bethel; P W Colson; J Franks; W El-Sadr
Journal:  Int J Tuberc Lung Dis       Date:  2010-09       Impact factor: 2.373

2.  High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.

Authors:  Kristine M Schmit; Mark N Lobato; Simona G Lang; Sherri Wheeler; Newton E Kendig; Sarah Bur
Journal:  J Public Health Manag Pract       Date:  2019 Mar/Apr

3.  Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.

Authors:  Mary C White; Jacqueline P Tulsky; Ju Ruey-Jiuan Lee; Lisa Chen; Joe Goldenson; Joanne Spetz; L Masae Kawamura
Journal:  J Correct Health Care       Date:  2012-03-14

4.  Treatment completion among TB patients returned to the community from a large urban jail.

Authors:  Seijeoung Kim; Kathleen Crittenden
Journal:  J Community Health       Date:  2007-04

5.  Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.

Authors:  Andreas Sandgren; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anke Stuurman; Anouk Oordt-Speets; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-05-17       Impact factor: 3.090

6.  Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail.

Authors:  Maria Juarez-Reyes; Mark Gallivan; Alexander Chyorny; Linda O'Keeffe; Neha S Shah
Journal:  Open Forum Infect Dis       Date:  2016-01-06       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.